Short Time to Progression under First-Line Chemotherapy Is a Negative Prognostic Factor for Time to Progression and Residual Survival under Second-Line Chemotherapy in Advanced Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|73|5-6|335-339

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.5-6, 2008-05, pp. : 335-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy

By  

Oncology Research and Treatment, Vol. 28, Iss. 10, 2005-09 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 175-180

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy in Advanced Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 61-69

Karger

Access to resources Recommend Favorite

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite